Last reviewed 2026-04-23 · How we verify

HMPL-306

HMPL-306 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.

HMPL-306 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells. Used for Cholangiocarcinoma with FGFR2 fusion or rearrangement, Other FGFR-altered solid tumors.

At a glance

Mechanism of action

HMPL-306 selectively targets FGFR kinases, which are frequently dysregulated in various solid tumors through mutations, amplifications, or translocations. By inhibiting FGFR-mediated signaling pathways, the drug suppresses tumor cell proliferation and survival in FGFR-dependent cancers. This mechanism is particularly relevant in tumors with FGFR alterations where the pathway drives oncogenic growth.

Approved indications

• Cholangiocarcinoma with FGFR2 fusion or rearrangement
• Other FGFR-altered solid tumors

Common side effects

• Hyperphosphatemia
• Diarrhea
• Fatigue
• Nausea
• Stomatitis

Key clinical trials

• A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations (PHASE1)
• A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH (PHASE1)
• A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia (PHASE3)
• Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations (PHASE1)
• Study on Mass Balance of [14C]HMPL-306（Isocitrate Dehydrogenase Inhibitor） in Healthy Chinese Adult Male Subjects (PHASE1)
• A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/Neoplasms (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.